Literature DB >> 21215802

Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse.

Laura K K Pacey1, Lilian Doss, Carlo Cifelli, Derek van der Kooy, Scott P Heximer, David R Hampson.   

Abstract

Fragile X syndrome (FXS), the most common cause of inherited mental retardation, is caused by the loss of the mRNA binding protein, FMRP. Persons with FXS also display epileptic seizures, social anxiety, hyperactivity, and autistic behaviors. The metabotropic glutamate receptor theory of FXS postulates that in the absence of FMRP, enhanced signaling though G-protein coupled group I metabotropic glutamate receptors in the brain contributes to many of the abnormalities observed in the disorder. However, recent evidence suggests that alterations in cellular signaling through additional G-protein coupled receptors may also be involved in the pathogenesis of FXS, thus providing impetus for examining downstream molecules. One group of signaling molecules situated downstream of the receptors is the regulator of G-protein signaling (RGS) proteins. Notably, RGS4 is highly expressed in brain and has been shown to negatively regulate signaling through Group I mGluRs and GABA(B) receptors. To examine the potential role for RGS4 in the pathogenesis of FXS, we generated FXS/RGS4 double knockout mice. Characterization of these mice revealed that a subset of FXS related phenotypes, including increased body weight, altered synaptic protein expression, and abnormal social behaviors, were rescued in the double knockout mice. Other phenotypes, such as hyperactivity and macroorchidism, were not affected by the loss of RGS4. These findings suggest that tissue and cell-type specific differences in GPCR signaling and RGS function may contribute to the spectrum of phenotypic differences observed in FXS.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21215802     DOI: 10.1016/j.mcn.2010.12.005

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  23 in total

1.  Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.

Authors:  Laura K K Pacey; Sujeenthar Tharmalingam; David R Hampson
Journal:  J Pharmacol Exp Ther       Date:  2011-06-02       Impact factor: 4.030

2.  Decreased home cage movement and oromotor impairments in adult Fmr1-KO mice.

Authors:  S J Bonasera; T R Chaudoin; E H Goulding; M Mittek; A Dunaevsky
Journal:  Genes Brain Behav       Date:  2017-03-29       Impact factor: 3.449

Review 3.  Avoiding mouse traps in schizophrenia genetics: lessons and promises from current and emerging mouse models.

Authors:  M Kvajo; H McKellar; J A Gogos
Journal:  Neuroscience       Date:  2011-07-27       Impact factor: 3.590

Review 4.  Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.

Authors:  Christina Gross; Elizabeth M Berry-Kravis; Gary J Bassell
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

Review 5.  Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back.

Authors:  Christina Gross; Anne Hoffmann; Gary J Bassell; Elizabeth M Berry-Kravis
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

6.  Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.

Authors:  Aimee V Franklin; Margaret K King; Valle Palomo; Ana Martinez; Lori L McMahon; Richard S Jope
Journal:  Biol Psychiatry       Date:  2013-09-13       Impact factor: 13.382

Review 7.  Roles for Regulator of G Protein Signaling Proteins in Synaptic Signaling and Plasticity.

Authors:  Kyle J Gerber; Katherine E Squires; John R Hepler
Journal:  Mol Pharmacol       Date:  2015-12-11       Impact factor: 4.436

8.  Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice.

Authors:  Shervin Gholizadeh; Jason Arsenault; Ingrid Cong Yang Xuan; Laura K Pacey; David R Hampson
Journal:  Neuropsychopharmacology       Date:  2014-07-07       Impact factor: 7.853

Review 9.  Glutamatergic candidate genes in autism spectrum disorder: an overview.

Authors:  Andreas G Chiocchetti; Hanna S Bour; Christine M Freitag
Journal:  J Neural Transm (Vienna)       Date:  2014-02-04       Impact factor: 3.575

10.  Absence of social conditioned place preference in BTBR T+tf/J mice: relevance for social motivation testing in rodent models of autism.

Authors:  Brandon L Pearson; Jaclyn K Bettis; Ksenia Z Meyza; Lace Y Yamamoto; D Caroline Blanchard; Robert J Blanchard
Journal:  Behav Brain Res       Date:  2012-04-27       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.